In a report released today, Matt Hewitt from Craig-Hallum maintained a Buy rating on OmniAb (OABI – Research Report), with a price target of $10.00. The company’s shares opened today at $4.55.
Hewitt covers the Healthcare sector, focusing on stocks such as Apyx Medical, Repligen, and Streamline Health Solutions. According to TipRanks, Hewitt has an average return of -8.1% and a 34.36% success rate on recommended stocks.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for OmniAb with a $10.25 average price target, representing a 125.27% upside. In a report released yesterday, TD Cowen also assigned a Buy rating to the stock with a $10.00 price target.
See the top stocks recommended by analysts >>
Based on OmniAb’s latest earnings release for the quarter ending June 30, the company reported a quarterly revenue of $6.95 million and a GAAP net loss of $14.73 million. In comparison, last year the company earned a revenue of $7.2 million and had a GAAP net loss of $10.28 million
Based on the recent corporate insider activity of 37 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of OABI in relation to earlier this year.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
OmniAb (OABI) Company Description:
Avista Public Acquisition Corp II is a blank check company.
Read More on OABI:
